Lung cancer remains as the main cause of cancer-related deaths worldwide. Over the last two decades, information about biology and pathogenesis of cancer has increased, immune checkpoint inhibitors (ICIs) have been introduced, and thus a significant period has started in treatment of solid cancers. This review discussed lung cancer in the framework of innovations in treatment, immunotherapy, and multidisciplinary approach to treatment. Non-small cell lung cancer (NSCLC) was the focal point of this article as it is the most frequent lung cancer type and the type of lung cancer which can ideally benefit from ICI treatment due to its characteristics. phis review is the first review in lurkish language, which aimed to raise the multidisciplinary awareness about immunotherapy approach in lung cancer treatment in all branches, primarily in chest diseases, and to provide information about its management. Moreover, this review has importance as it presents the remarkable results of recent clinical trials on the use of ICIs in NSCLC treatment. Immunotherapy has initiated a new era in cancer treatment; the specific mechanism of action of ICIs has resulted in a group of some new adverse events, among which pneumonitis is particularly important and when necessary, patients are needed to be consulted with relevant specialties about adverse events. Lung cancer treatment should be planned specific to each patient by considering patient characteristics, histological features, and genetic status and specialty areas of chest diseases, thoracic surgery, medical oncology, radiation oncology, pathology, and radiology should collaborate together for diagnostic evaluation and optimal treatment of a lung cancer patient. Moreover, family physicians may have an important role in early diagnosis of lung cancer and in preventing lung cancer by encouraging their patients regarding tobacco cessation. Moreover, screening studies for lung cancer should be targeted to create awareness in society and for early diagnosis.